| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/08/2022 | 2.19% | HC Wainwright & Co. | $30 → $34 | Downgrades | Buy → Neutral |
| 02/07/2022 | -9.83% | HC Wainwright & Co. | $28 → $30 | Maintains | Buy |
| 11/15/2021 | -15.84% | HC Wainwright & Co. | $27 → $28 | Maintains | Buy |
| 08/09/2021 | -18.85% | HC Wainwright & Co. | $30 → $27 | Maintains | Buy |
| 05/10/2021 | -9.83% | HC Wainwright & Co. | $32 → $30 | Maintains | Buy |
| 02/24/2021 | -3.82% | HC Wainwright & Co. | $34 → $32 | Maintains | Buy |
| 02/08/2021 | 2.19% | HC Wainwright & Co. | $30 → $34 | Maintains | Buy |
| 11/16/2020 | -9.83% | HC Wainwright & Co. | $34 → $30 | Maintains | Buy |
| 07/27/2020 | 2.19% | HC Wainwright & Co. | → $34 | Initiates Coverage On | → Buy |
| 05/01/2019 | -72.95% | Canaccord Genuity | $11 → $9 | Maintains | Sell |
| 05/01/2019 | -66.94% | Piper Sandler | $15 → $11 | Upgrades | Underweight → Neutral |
| 04/03/2019 | — | Canaccord Genuity | Downgrades | Hold → Sell | |
| 01/26/2018 | -51.91% | Canaccord Genuity | $14 → $16 | Maintains | Hold |
Meridian Bioscience Questions & Answers
The latest price target for Meridian Bioscience (NASDAQ: VIVO) was reported by HC Wainwright & Co. on July 8, 2022. The analyst firm set a price target for $34.00 expecting VIVO to rise to within 12 months (a possible 2.19% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Meridian Bioscience (NASDAQ: VIVO) was provided by HC Wainwright & Co., and Meridian Bioscience downgraded their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Meridian Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Meridian Bioscience was filed on July 8, 2022 so you should expect the next rating to be made available sometime around July 8, 2023.
While ratings are subjective and will change, the latest Meridian Bioscience (VIVO) rating was a downgraded with a price target of $30.00 to $34.00. The current price Meridian Bioscience (VIVO) is trading at is $33.27, which is within the analyst's predicted range.